ANTIBODY TO CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS-PNEUMONIAE - PREVALENCE, PERSISTENCE, AND RESPONSE TO REVACCINATION

被引:116
作者
MUSHER, DM
GROOVER, JE
ROWLAND, JM
WATSON, DA
STRUEWING, JB
BAUGHN, RE
MUFSON, MA
机构
[1] BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA
[2] BAYLOR COLL MED, DEPT MICROBIOL IMMUNOL, HOUSTON, TX 77030 USA
[3] NAVY ENVIRONM & PREVENT MED UNIT 5, SAN DIEGO, CA USA
[4] MARSHALL UNIV, SCH MED, DEPT MED, HUNTINGTON, WV 25701 USA
[5] VET AFFAIRS MED CTR, HUNTINGTON, WV USA
关键词
D O I
10.1093/clinids/17.1.66
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prevalence of immunity to Streptococcus pneumoniae in the adult population of the United States is unknown. In the study described herein, military recruits had anticapsular IgG antibody to only 15% of common pneumococcal serotypes, whereas working men and elderly men had IgG antibody to 33% and 34% of the common serotypes, respectively (P < .001). Among eight elderly subjects, the prevalence of IgG antibody to capsular polysaccharides increased from 30% to 78% after pneumococcal vaccination; 6 years thereafter, the rate of positive reactions had declined to 58% and IgG levels had declined substantially. With revaccination, IgG levels returned to within (+/-) 40% of the original postvaccination levels. IgM and IgG antibody appeared or began to increase in titer 6 days after vaccination; the rate and degree of response were the same after the first and second exposures. Since most individuals rapidly develop IgG antibody after colonization by S. pneumoniae and since IgG confers immunity, these data suggest that pneumonia is infrequent among healthy adults not because preexisting immunity is widespread but because-with colonization-an immune response develops rapidly, preceding specific events that might lead to infection. Our findings support recommended vaccination procedures and suggest that wider application in subsets of healthy younger adults should be considered.
引用
收藏
页码:66 / 73
页数:8
相关论文
共 50 条
[1]  
AMMANN AJ, 1980, P SOC EXP BIOL MED, V164, P312
[2]  
[Anonymous], [No title captured]
[3]  
[Anonymous], PNEUMONIA SPECIAL RE
[4]   PNEUMOCOCCAL VACCINE EFFICACY IN SELECTED POPULATIONS IN THE UNITED-STATES [J].
BOLAN, G ;
BROOME, CV ;
FACKLAM, RR ;
PLIKAYTIS, BD ;
FRASER, DW ;
SCHLECH, WF .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :1-6
[5]  
BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010
[6]  
BRACONIER JH, 1984, SCAND J INFECT DIS, V16, P161, DOI 10.3109/00365548409087136
[7]  
CECIL RL, 1930, TXB MED
[8]   CORRELATION OF SERUM OPSONINS WITH INVITRO PHAGOCYTOSIS OF STREPTOCOCCUS-PNEUMONIAE [J].
CHUDWIN, DS ;
ARTRIP, SG ;
KORENBLIT, A ;
SCHIFFMAN, G ;
RAO, S .
INFECTION AND IMMUNITY, 1985, 50 (01) :213-217
[9]   Immunity reactions of human subjects to strains of pneumococci other than Types I, II and III [J].
Finland, M ;
Sutliff, WD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1933, 57 (01) :95-109
[10]   Bacteriological and immunological studies in families with pneumococcic infections: The development of type-specific antibodies in healthy contact carriers [J].
Finland, M ;
Tilghman, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1936, 15 (05) :501-508